Navigation Links
Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010
Date:10/26/2010

REDWOOD CITY, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Monday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2010 financial results. The call and webcast will follow the release of the third quarter financial results after market close.

Conference Call Details

To access the live conference call on November 8 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally.  Please dial in approximately ten minutes prior to the start of the call.  A telephone replay will be available beginning approximately two hours after the call through November 15, and may be accessed by dialing (800) 642-1687 from the United States and Canada or +1(706) 645-9291 internationally. The replay passcode is 19819777.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com.  Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health, Inc.

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of June 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 160,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or registered trademarks of Genomic Health, Inc.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
2. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
3. Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement
4. Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
5. Genomic Health to Present at Two Upcoming Investor Conferences
6. Ingenuity Systems Announces Toxicogenomics Best Practices White Paper
7. J. Craig Venter Institute Hosts Genomics Education Program for DC Metro Area Teachers
8. NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010
9. Sirius Genomics Announces Appointment of Senior Director of Business Development
10. SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies
11. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... 16, 2017  Champions Oncology, Inc. (NASDAQ: ... sale of advanced technology solutions and products to personalize ... the addition of new cohorts of PDX models to ... will expand Champions, product line in hepatocellular cancer, breast ... AML, and non-small cell lung cancer (including EGFR mutation; ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):